Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Werewolf Therapeutics, Inc. Market Cap
The Werewolf Therapeutics, Inc. (HOWL) share price is expected to increase by 545.16% over the next year. This is based on calculating the average 12-month share price estimate provided by 6 stock analysts who have covered HOWL. Price targets range from $8 at the low end to $15 at the high end. The current analyst consensus for HOWL is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Werewolf Therapeutics, Inc. has a total of 6 Wall St Analyst ratings. There are 6 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Werewolf Therapeutics, Inc. will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of HOWL.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Nov 19, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Jul 2, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Jun 26, 2024 |
| Reni Benjamin JMP Securities | Market Outperform | $12 | Reiterates | Jun 26, 2024 |
| Reni Benjamin JMP Securities | Market Outperform | $12 | Reiterates | Jun 4, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Jun 3, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | May 24, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | May 6, 2024 |
| Reni Benjamin JMP Securities | Market Outperform | $12 | Reiterates | May 6, 2024 |
| Reni Benjamin JMP Securities | Market Outperform | $12 | Initiates | Apr 3, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Maintains | Mar 7, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Nov 15, 2023 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Oct 31, 2023 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Sep 19, 2023 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Sep 15, 2023 |
Wedbush | Outperform | Initiates | Aug 24, 2023 | |
HC Wainwright & Co. | Buy | Reiterates | Aug 10, 2023 | |
| Michael King EF Hutton | Buy | $8.3 | Assumes | May 25, 2023 |
B of A Securities | Buy | Reiterates | May 15, 2023 | |
| Jason Zemansky B of A Securities | Buy | $10 | Maintains | May 12, 2023 |
When did it IPO
2021
Staff Count
45
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Daniel J. Hicklin Ph.D.
Market Cap
$87.3M
In 2023, HOWL generated $19.9M in revenue, which was a increase of 21.60% from the previous year. This can be seen as a signal that HOWL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 20 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Werewolf Therapeutics, Inc. (Nasdaq: HOWL) executives will speak at the Evercore ISI HealthCONx Conference on December 5, 2024, discussing their innovative cancer therapies.
Why It Matters - Werewolf Therapeutics' participation in a prominent healthcare conference highlights its visibility and potential for investor interest, particularly in the lucrative biotech sector focused on cancer treatments.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Interim phase 1 trial results for WTX-330, a tumor-activated IL-12 prodrug, show favorable tolerability and promising efficacy signals, indicating potential for further development.
Why It Matters - The update on WTX-330 suggests promising efficacy and safety, potentially boosting the company's stock value and attracting investment interest in oncology innovations.
Fri, 04 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Werewolf Therapeutics (Nasdaq: HOWL) will present two posters at the SITC 39th Annual Meeting from November 6-10, 2024, focusing on its immune-stimulating cancer therapies.
Why It Matters - Werewolf Therapeutics’ presentation at a major oncology conference highlights its innovative pipeline, potentially attracting investor interest and impacting stock performance based on market reception.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Positive data from the Phase 1/1b clinical trial of WTX-124 was presented at the ASCO Annual Meeting, indicating progress in its development.
Why It Matters - Positive Phase 1/1b trial data for WTX-124 may indicate potential market success and increased investor confidence in the company’s pipeline, impacting stock performance and future funding.
Thu, 08 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Werewolf Therapeutics, Inc. (HOWL) reported a quarterly loss of $0.43 per share, exceeding the expected loss of $0.38 and worsening from a loss of $0.14 per share a year prior.
Why It Matters - Werewolf Therapeutics' larger-than-expected quarterly loss signals potential operational challenges, possibly affecting investor confidence and stock performance.
Mon, 01 Jul 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Werewolf Therapeutics, Inc. reports positive clinical trial results for WTX-124 and promising data for WTX-330. The company currently has a stable cash position but may need to manage cash burn soon.
Why It Matters - Positive clinical trial results for WTX-124 and WTX-330 could enhance Werewolf Therapeutics' market position and valuation, while cash burn concerns may affect future funding and operations.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
